Jessica R. Bobbitt

Jessica R. Bobbitt

Auto-generated profile, based on publicly available information

Jessica R. Bobbitt

Department of Pathology School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Endocrinology
Verified
Journal Article
Closed access
PDF file
JBJessica R Bobbitt
Jessica R Bobbitt
DSDarcie D Seachrist
Darcie D Seachrist
RKRuth Keri
Ruth Keri
The advent of sequencing technologies for assessing chromosome conformations has provided a wealth of information on the organization of the 3-dimensional genome and its role in cancer progression. It is now known that changes in chromatin folding and accessibility can promote aberrant activation or repression of transcriptional programs that can drive tumorigenesis and progression in diverse cancers. This includes breast cancer, which comprises several distinct subtypes defined by their unique transcriptomes that dictate treatment response and patient outcomes. Of these, basal-like breast cancer is an aggressive subtype controlled by a pluripotency-enforcing transcriptome. Meanwhile, the more differentiated luminal subtype of breast cancer is driven by an estrogen receptor-dominated transcriptome that underlies its responsiveness to antihormone therapies and conveys improved patient outcomes. Despite the clear differences in molecular signatures, the genesis of each subtype from normal mammary epithelial cells remains unclear. Recent technical advances have revealed key distinctions in chromatin folding and organization between subtypes that could underlie their transcriptomic and, hence, phenotypic differences. These studies also suggest that proteins controlling particular chromatin states may be useful targets for treating aggressive disease. In this review, we explore the current state of understanding of chromatin architecture in breast cancer subtypes and its potential role in defining their phenotypic characteristics.

16 May 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KPKatrina M. Piemonte
Katrina M. Piemonte
BWBryan M. Webb
Bryan M. Webb
JBJessica R. Bobbitt
Jessica R. Bobbitt
PMParth R. Majmudar
Parth R. Majmudar
LCLeslie Cuellar-Vite
Leslie Cuellar-Vite
RKRuth Keri
Ruth Keri
Chromatin organization is highly dynamic and modulates DNA replication, transcription, and chromosome segregation. Condensin is essential for chromosome assembly during mitosis and meiosis, as well as maintenance of chromosome structure during interphase. While it is well established that sustained condensin expression is necessary to ensure chromosome stability, the mechanisms that control its expression are not yet known. Herein, we report that disruption of cyclin-dependent kinase 7 (CDK7), the core catalytic subunit of CDK-activating kinase, leads to reduced transcription of several condensin subunits, including structural maintenance of chromosomes 2 (SMC2). Live and static microscopy revealed that inhibiting CDK7 signaling prolongs mitosis and induces chromatin bridge formation, DNA double-strand breaks, and abnormal nuclear features, all of which are indicative of mitotic catastrophe and chromosome instability. Affirming the importance of condensin regulation by CDK7, genetic suppression of the expression of SMC2, a core subunit of this complex, phenocopies CDK7 inhibition. Moreover, analysis of genome-wide chromatin conformation using Hi-C revealed that sustained activity of CDK7 is necessary to maintain chromatin sublooping, a function that is ascribed to condensin. Notably, the regulation of condensin subunit gene expression is independent of superenhancers. Together, these studies reveal a new role for CDK7 in sustaining chromatin configuration by ensuring the expression of condensin genes, including SMC2.

16 January 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JBJessica R. Bobbitt
Jessica R. Bobbitt
LCLeslie Cuellar-Vite
Leslie Cuellar-Vite
KWKristen L. Weber-Bonk
Kristen L. Weber-Bonk
MYMarlee R. Yancey
Marlee R. Yancey
PMParth R. Majmudar
Parth R. Majmudar
RKRuth Keri
Ruth Keri
Selective inhibitors that target cyclin-dependent kinases 4 and 6 (CDK4/6i) are approved by the U.S. Food and Drug Administration (FDA) for treatment of a subset of breast cancers and are being evaluated in numerous clinical trials for other cancers. Despite this advance, a subset of tumors are intrinsically resistant to these drugs and acquired resistance is nearly inevitable. Recent mechanistic evidence suggests that in addition to stalling the cell cycle, the antitumor effects of CDK4/6i involve the induction of chromosomal instability (CIN). Here, we exploit this mechanism by combining CDK4/6i with other instability-promoting agents to induce maladaptive CIN and irreversible cell fates. Specifically, dual targeting of CDK4/6 and the mitotic kinase NEK2 in vitro drives centrosome amplification and the accumulation of CIN that induces catastrophic mitoses, cell cycle exit, and cell death. Dual targeting also induces CIN in vivo and significantly decreases mouse tumor volume to a greater extent than either drug alone, without inducing overt toxicity. Importantly, we provide evidence that breast cancer cells are selectively dependent on NEK2, but nontransformed cells are not, in contrast with other mitotic kinases that are commonly essential in all cell types. These findings implicate NEK2 as a potential therapeutic target for breast cancer that could circumvent the dose-limiting toxicities that are commonly observed when blocking other mitotic kinases. Moreover, these data suggest that NEK2 inhibitors could be used to sensitize tumors to FDA-approved CDK4/6i for the treatment of breast cancers, improving their efficacy and providing a foundation for expanding the patient population that could benefit from CDK4/6i.

15 January 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
LCLeslie Cuellar-Vite
Leslie Cuellar-Vite
EDElyse M. Donaubauer
Elyse M. Donaubauer
KWKristen L. Weber-Bonk
Kristen L. Weber-Bonk
JBJessica R. Bobbitt
Jessica R. Bobbitt
NINatasha N. Ingles
Natasha N. Ingles
RKRuth Keri
Ruth Keri
EGFR is a highly expressed driver of many cancers, yet the utility of EGFR inhibitors (EGFRi) is limited to cancers that harbor sensitizing mutations in the EGFR gene because of dose-limiting toxicities. Rather than conventionally blocking the kinase activity of EGFR, we sought to reduce its transcription as an alternative approach to broaden the therapeutic window for EGFR inhibitors targeting wild-type (WT) or mutant EGFR. We found that YES1 is highly expressed in triple-negative breast cancer (TNBC) and drives cell growth by elevating EGFR levels. Mechanistically, YES1 stimulates EGFR expression by signaling to JNK and stabilizing the AP-1 transcription factor c-Jun. This effect extends beyond TNBC as YES1 also sustains EGFR expression in non–small cell lung cancer cells, including those that harbor the EGFR gatekeeper mutation T790M. The novel ability of YES1 to regulate the expression of WT and mutant EGFR mRNA and protein provides a potential therapeutic opportunity of utilizing YES1 blockade to broadly increase the efficacy of EGFR inhibitors. Indeed, we observed synergy within in vitro and in vivo models of TNBC and non–small cell lung cancer, even in the absence of EGFR-activating mutations. Together, these data provide a rationale for blocking YES1 activity as an approach for improving the efficacy of EGFR-targeting drugs in cancers that have generally been refractory to such inhibitors. Implications: YES1 sustains EGFR expression, revealing a therapeutic vulnerability for increasing the efficacy of EGFR inhibitors by lowering the threshold for efficacy in tumors driven by the WT or mutant receptor.

17 June 2026
Verified
Other
Open access
LCLeslie Cuellar-Vite
Leslie Cuellar-Vite
EDElyse M. Donaubauer
Elyse M. Donaubauer
KWKristen L. Weber-Bonk
Kristen L. Weber-Bonk
JBJessica R. Bobbitt
Jessica R. Bobbitt
NINatasha N. Ingles
Natasha N. Ingles
RKRuth Keri
Ruth Keri
Figure S8 shows mouse weight of YES1 and EGFR inhibitor treatments shown in Figure 6.

17 June 2026
Verified
Other
Open access
LCLeslie Cuellar-Vite
Leslie Cuellar-Vite
EDElyse M. Donaubauer
Elyse M. Donaubauer
KWKristen L. Weber-Bonk
Kristen L. Weber-Bonk
JBJessica R. Bobbitt
Jessica R. Bobbitt
NINatasha N. Ingles
Natasha N. Ingles
RKRuth Keri
Ruth Keri
Figure S5 shows blots of total protein staining from Figure 3 and blots with quantitation of phosphorylated STAT3, ERK, AKT, and p38 following YES1 silencing.